A detailed history of Marshall Wace, LLP transactions in Vor Biopharma Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 116,635 shares of VOR stock, worth $100,306. This represents 0.0% of its overall portfolio holdings.

Number of Shares
116,635
Previous 81,114 43.79%
Holding current value
$100,306
Previous $81,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.7 - $1.1 $24,864 - $39,073
35,521 Added 43.79%
116,635 $81,000
Q2 2024

Aug 14, 2024

BUY
$1.0 - $2.2 $4,800 - $10,560
4,800 Added 6.29%
81,114 $81,000
Q1 2024

May 15, 2024

BUY
$1.8 - $2.85 $137,365 - $217,494
76,314 New
76,314 $180,000
Q1 2023

May 15, 2023

BUY
$4.68 - $6.96 $91,737 - $136,429
19,602 Added 64.3%
50,089 $269,000
Q4 2022

Feb 14, 2023

BUY
$3.77 - $7.43 $114,935 - $226,518
30,487 New
30,487 $202,000

Others Institutions Holding VOR

About Vor Biopharma Inc.


  • Ticker VOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,056,300
  • Market Cap $32.7M
  • Description
  • Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...
More about VOR
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.